Soligenix, Inc. - Common Stock (SNGX)
2.9300
+1.6800 (134.40%)
NASDAQ · Last Trade: Jul 31st, 6:47 PM EDT
Detailed Quote
| Previous Close | 1.250 |
|---|---|
| Open | 1.890 |
| Bid | 2.800 |
| Ask | 2.810 |
| Day's Range | 1.660 - 5.380 |
| 52 Week Range | 1.090 - 5.400 |
| Volume | 376,064,784 |
| Market Cap | 9.56M |
| PE Ratio (TTM) | -0.6830 |
| EPS (TTM) | -4.3 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 2,437,636 |
Chart
About Soligenix, Inc. - Common Stock (SNGX)
Soligenix Inc. is a biopharmaceutical company focused on developing innovative therapies for significant unmet medical needs. The company specializes in the research and clinical development of proprietary products aimed at treating rare diseases, as well as products intended for biodefense applications. With a strong emphasis on developing treatments for conditions such as oral mucositis and acute radiation syndrome, Soligenix takes a multi-faceted approach that includes leveraging its drug development platforms and engaging in collaborations with various stakeholders to advance its pipeline. The company’s dedication to improving patient outcomes drives its commitment to delivering safe and effective therapeutic options. Read More
News & Press Releases
Loop Industries, Inc. (Nasdaq: LOOP) has launched Twist™, a branded, high-performance polyester resin made entirely from textile waste. Targeted at the fashion, sportswear, and home textile sectors, Twist™ delivers virgin-quality performance , full traceability, and up to 81% fewer CO₂ emissions than fossil-based alternatives.
Via AB Newswire · July 31, 2025
Let's have a look at what is happening on the US markets one hour before the close of the markets on Thursday. Below you can find the top gainers and losers in today's session.
Via Chartmill · July 31, 2025
Get a pulse on the US markets on Thursday by checking out the most active stocks in today's session. Discover the stocks that are leading the way in terms of trading volume and market activity.
Via Chartmill · July 31, 2025
Via Benzinga · July 31, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via Chartmill · July 31, 2025
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Achieves Biological Efficacy in Phase 2a SGX945 Study for Behçet’s Disease
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing products for rare diseases, has completed its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in Behçet’s Disease, meeting the objective of demonstrating biological efficacy. In the open-label trial, SGX945 achieved a 40% improvement in the primary ulcer endpoint versus a historical placebo group from the apremilast (Otezla(R)) Phase 3 study, matching or exceeding apremilast outcomes despite treatment stopping at four weeks. Seven of eight patients reported reduced ulcer duration, number and pain, with benefits persisting through the follow-up period and no treatment-related adverse events reported. CEO Christopher J. Schaber said the results support advancing SGX945, including reformulation for home-based subcutaneous administration, as part of a broader strategy to address unmet needs in Behçet’s and other innate immune-related inflammatory conditions.
Via Investor Brand Network · July 31, 2025
Soligenix reports positive Phase 2a trial results for SGX945 in Behçet's disease, showing strong efficacy and no adverse events compared to apremilast.
Via Benzinga · July 31, 2025
Via Benzinga · July 31, 2025
BioMedNewsBreaks — Targeting the Unmet: Soligenix Inc. (NASDAQ: SNGX) Building Portfolio for Rare Conditions
According to a recent article, “Behçet’s disease is rare, with prevalence estimates varying from 0.12 to 7.5 per 100,000 in the United States and Europe… Behçet’s disease is believed to be an autoimmune illness with both genetic and environmental components. Symptoms are most severe in young adulthood and generally ameliorate with age… Treatment involves medications designed to ease symptoms and prevent serious complications, such as blindness. Even with treatment, oral and genital flares can continue to occur for many patients and significantly affect quality of life and productivity. In addition, treatments can be associated with adverse effects, underscoring the need for more targeted and effective therapies.”
Via Investor Brand Network · July 25, 2025
Oral mucositis, a debilitating side effect of cancer therapy with no FDA-approved treatment, continues to wreak havoc on patients undergoing cancer care, prompting an urgent need for effective interventions. Soligenix (NASDAQ: SNGX) is stepping forward with SGX942, a novel therapeutic aimed at alleviating this condition, with promising phase 3 data showing substantial improvements in the duration and severity of mucositis in head and neck cancer patients .
Via Investor Brand Network · July 24, 2025
Global Vaccination Goals at Risk as 14 Million Kids Miss Crucial Shots
Latest UN data indicates that at least 14 million kids didn’t receive life-saving shots of vaccines against tetanus, whooping cough and diphtheria in 2024. This threatens the attainment of global vaccination goals.
Via Investor Brand Network · July 24, 2025
Soligenix Inc. (NASDAQ: SNGX) Reports Strong Results in ‘Real-World’ Trial
Soligenix (NASDAQ: SNGX) is reporting encouraging interim outcomes from the ongoing investigator-initiated study (“IIS”) of its HyBryte(TM) (synthetic hypericin) program, under the direction of Ellen Kim, MD, director of the Penn Cutaneous Lymphoma Program. Kim is a leading enroller in Soligenix’s phase 3 FLASH study and serves as principal investigator for the confirmatory phase 3 FLASH2 trial, which recent data from the IIS indicates is delivering promising treatment success in early-stage cutaneous T-cell lymphoma (“CTCL”).
Via Investor Brand Network · July 18, 2025
InvestorNewsBreaks – Zacks Research Releases Updated Report as Soligenix Inc. (NASDAQ: SNGX) Eyes Upcoming ‘Key Catalysts’
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company targeting rare diseases, was spotlighted in a July 10 Zacks Small-Cap Research report that presented a favorable analysis, noting that the company is anticipating a number of key catalysts in the second half of 2025, including progress on its current phase 3 FLASH2 trial of HyBryte(TM) for the treatment of early-stage cutaneous T cell lymphoma (“CTCL”).
Via Investor Brand Network · July 15, 2025
Dutch Startup Develops Highly Sensitive Field Test for Infectious Diseases
Spotlight Diagnostics, a startup based in Eindhoven, Netherlands, is developing a test kit that will enable personnel to rapidly test for infectious diseases without requiring lab facilities . The kit targets infectious diseases like malaria, Chlamydia, gonorrhea and others that take a huge toll on human life.
Via Investor Brand Network · July 11, 2025
BioMedNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Targets Multiple 2025–2026 Catalysts Across Rare Disease Pipeline
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company developing therapies for rare diseases with unmet medical needs, issued a shareholder update outlining key clinical and strategic milestones. President and CEO Dr. Christopher J. Schaber highlighted upcoming data readouts for lead candidates, including Phase 3 FLASH 2 results for HyBryte(TM) (synthetic hypericin) in cutaneous T-cell lymphoma expected in 2H 2026, and multiple updates in 3Q and 4Q 2025 across psoriasis (SGX302) and Behçet’s Disease (SGX945). An investigator-initiated study also showed a 75% success rate at 18 weeks. The company projects HyBryte(TM) peak U.S. annual sales of over $90 million and global opportunities exceeding $2 billion across its pipeline. With approximately $7 million in cash and active exploration of partnerships and M&A, Soligenix aims to extend its cash runway into 1Q 2026 while preparing for global regulatory filings and potential commercialization.
Via Investor Brand Network · July 9, 2025
Soligenix Inc. (NASDAQ: SNGX) Highlights Encouraging Phase 3 Progress for HyBryte(TM) in Investment Webinar
In a recent webinar hosted by Allele Capital, Soligenix (NASDAQ: SNGX) executives Dr. Christopher Schaber and Dr. Christopher Pullion shared detailed updates on the company’s HyBryte(TM) (synthetic hypericin) clinical development ( https://ibn.fm/dz7eO ). The event offered an in-depth look at Soligenix’s ongoing confirmatory phase 3 trial for cutaneous T-cell lymphoma (“CTCL”), a rare non-Hodgkin’s lymphoma, and discussed promising data emerging from an investigator-initiated study conducted at the University of Pennsylvania. Soligenix, a late-stage biopharmaceutical company, is dedicated to developing and commercializing treatments for rare diseases and unmet medical needs, and HyBryte(TM) represents the company’s lead asset aimed at transforming the treatment landscape for CTCL.
Via Investor Brand Network · July 2, 2025
Via Benzinga · July 2, 2025
Research Finds That Pesticides Disrupt Inflammation-Linked Bacteria
Existing scientific information shows that pesticides are toxic to the microorganisms in the gut, and a new preclinical study has mapped the specific impacts that compounds in pesticides have on microbes in the human digestive system. One surprising finding emerged regarding how these pesticide compounds affect the inflammatory system in the body.
Via Investor Brand Network · July 1, 2025
Via Benzinga · July 1, 2025
InvestorNewsBreaks – Soligenix Inc. (NASDAQ: SNGX) Advancing Novel Immunotherapy to Combat Antibiotic Resistance
Soligenix (NASDAQ: SNGX) is at the forefront of the effort as the medical community urgently seeks alternative treatments for bacterial infections in the face of escalating antibiotic resistance. The company’s SGX943 therapy “is based on dusquetide, an Innate Defense Regulator (‘IDR’) that modulates the body’s immune response rather than directly targeting bacteria. By enhancing the innate immune system, SGX943 promotes the clearance of infections and reduces inflammation, offering a broad-spectrum approach to bacterial infections,” reads a recent article. “The company’s portfolio encompasses both specialized biotherapeutics and public health solutions, targeting areas with significant unmet medical needs.”
Via Investor Brand Network · June 30, 2025
Via Benzinga · June 24, 2025